Das Auge in der Inneren Medizin: Die diabetische Retinopathie

Diagnostik und Therapie der diabetischen Retinopathie haben in den zurückliegenden 15 Jahren riesige Fortschritte gemacht. Hochpräzise bildgebende Verfahren und die neu eingeführte pharmakologische Therapie mit direkt in das Auge verabreichten Wirkstoffen zur Hemmung des Vascular Endothelial Growth Factor (VEGF) oder Kortikosteroiden haben langjährige Standards geradezu revolutioniert. Die relevanten Aspekte erläutert dieser Beitrag.

Abstract

Diabetic retinopathy has seen tremendous progress in diagnostic tools and treatment in recent 15 years. Sight threatening stages like proliferative diabetic retinopathy (PDR) and diabetic macular edema (DME) can be treated much more effectively now. The recognition of vascular endothelial growth factor (VEGF) as a driver of proliferation and macular edema has led to the development of VEGF inhibiting drugs such as antibodies (Bevacizumab), fragments of an antibody (Ranibizumab), or a so called VEGF trap (Aflibercept). Laser treatment is no longer a gold standard. Today laser therapy is part of a combined treatment strategy. DME can be monitored quantitatively by ocular coherence tomography (OCT) measurements. For non-responders to VEGF inhibiting drugs, we have secondline corticosteroidal implants. However, screening examinations and early diagnosis of DME and PDR remain crucial. The same accounts for the collaboration of opthalmologists, general practioners, and diabetologists. Good control of diabetes and blood pressure is still important.

Schlüsselwörter

diabetische Retinopathie - Makulaödem - VEGF-Inhibitoren - Laser

Key words

diabetic retinopathy - macular edema - VEGF inhibitors - laser

Publication History

Article published online:
13 July 2021

• Literatur

• 1 Schmidt-Erfurth U, Garcia-Arumi J, Bandello F. et al. Guidelines for the Management of Diabetic Macular Edema by the European Society of Retina Specialists (EURETINA). Ophthalmologica 2017; 237: 185-222
• 2 Deutsche Ophthalmologische Gesellschaft (DOG), Retinologische Gesellschaft (RG), Bundesverband der Augenärzte Deutschlands (BVA). Stellungnahme zur Therapie des diabetischen Makulaödems. Stand August 2019. Klin Monbl Augenheilkd 2020; 237: 325-352 DOI: 10.1055/a-1097-344009/19.
• 3 The Early Treatment Diabetic Retinopathy research Group ETDRS. Early Photocoagulation for Diabetic Retinopathy. ETDRS Report No. 9. Ophthalmology 1991; 98: 766-785
• 4 Flynn Jr HW, Chew EY, Simons BD. et al. Pars-Plana-Vitrectomy in the Early Treatment Diabetic Retinopathy Study. ETDRS Report No. 17. Ophthalmology 1992; 99: 1351-1357
• 5 Bundesärztekammer (BÄK), Kassenärztliche Bundesvereinigung (KBV), Arbeitsgemeinschaft der wissenschaftlichen Medizinischen Fachgesellschaften (AWMF). Nationale Versorgungs-Leitlinie Prävention und Therapie von Netzhautkomplikationen bei Diabetes – Langfassung, 2. Auflage (2015). https://www.leitlinien.de/mdb/downloads/nvl/diabetes-mellitus/dm-netzhautkomplikationen-2aufl-vers2-lang.pdf ; Stand: 16.04.202
• 6 Lemmen KD, Bertram B, Agostini J. et al. Stadieneinteilung und Therapie der diabetischen Retinopathie und Makulopathie – ein Update. Z prakt Augenheilkd 2016; 37: 567-577
• 7 Ziemssen F, Lemmen KD, Bertram B. et al. Nationale „Versorgungsleitlinie (NVL) Diabetische Retinopathie. 2. Auflage der NVL zur Therapie der diabetischen Retinopathie. Ophthalmologe 2016; 113: 623-638
• 8 The Early Treatment Diabetic Retinopathy research Group ETDRS. Early Photocoagulation for Diabetic Retinopathy. ETDRS Report No. 9. Ophthalmology 1992; 98: 766-785
• 9 DRCRnetwork: Wells JA, Glassman AR, Ayala AR et al. Protocol T: Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema. N Engl J Med 2015; 372: 1193-1203 DOI: 10.1056/NEJMoa1414264.
• 10 Ulbig M, Höh H, Schmickler S. et al. Treatment Reality with Ranibizumab in Clinical Routine Use for Patients with Diabetic Macular Edema: 1 Year Results of the German POLARIS Cohort. Ophthalmologe 2019; 116: 631-639
• 11 DRCRnetwork: Elman MJ, Aiello LP, Beck RW et al. Protocol i: Randomized Trial Evaluating Ranibizumab plus prompt or deferred Laser or Triamcinolone plus prompt Laser for Diabetic Macular Edema. Ophthalmology 2010; 117: 1064-1077
• 12 FAME Study Group: Campochiaro PA, Brown DM, Pearson A et al. Sustained Delivery Fluocinolone Acetonide Vitreous Inserts Provide Benefit for at Least 3 Years in Patients With Diabetic Macular Edema. Ophthalmology 2012; 119: 2125-2132
• 13 DRCRnetwork: Gross JG, Glassman AR, Jampol LM et al. Protocol S: Panretinal Photocoagulation vs Intravitreous Ranibizumab for Proliferative Diabetic Retinopathy. A Randomized Clinical Trial. JAMA 2015; 314: 2137-2146 DOI: 10.1001/jama.2015.15217.
• 14 Deutsche Ophthalmologische Gesselschaft, Retinologische Gesellschaft, Bundesverband der Augenärzte Deutschlands. Ergänzende Stellungnahme zur Therapie der proliferativen diabetischen Retinopathie, 11/2019. Ophthalmologe 2020; 117: 755-759 DOI: 10.1007/s00347-020-01116-3.